Oligopeptides for Cancer Immunotherapy
Cytotoxic T lymphocytes (CTL) kill tumour cells upon recognition of oligopeptides derived from tumour-associated antigens (TAA). These are presented by major histocompatibility complex (MHC) class I molecules on the surface of the tumour cells. TAA of certain categories differ with respect to their tumour specificity: mutated antigens and so-called “cancer/germ line” (C/G) antigens are considered strictly or highly tumour specific whereas differentiation antigens are expressed in tumours and the tissues the tumours originate from. The expression of C/G antigens was demonstrated in a variety of cancer types.
Further Information: PDF
IMG Innovations-Management GmbH
Phone: +49 (0)631/31668-50
Contact
Dr. Klaus Kobek
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Sea slugs inspire highly stretchable biomedical sensor
USC Viterbi School of Engineering researcher Hangbo Zhao presents findings on highly stretchable and customizable microneedles for application in fields including neuroscience, tissue engineering, and wearable bioelectronics. The revolution in…
Twisting and binding matter waves with photons in a cavity
Precisely measuring the energy states of individual atoms has been a historical challenge for physicists due to atomic recoil. When an atom interacts with a photon, the atom “recoils” in…
Nanotubes, nanoparticles, and antibodies detect tiny amounts of fentanyl
New sensor is six orders of magnitude more sensitive than the next best thing. A research team at Pitt led by Alexander Star, a chemistry professor in the Kenneth P. Dietrich…